BMY - Mid-stage study underway on VBL's VB-111 in colorectal cancer September, 10 2020 10:22 AM Bristol-Myers Squibb Company The first two participants have been enrolled in a Phase 2 clinical trial evaluating the combination of VBL Therapeutics' (VBLT +0.9%) VB-111 and Bristol Myers Squibb's (BMY -0.1%) Opdivo (nivolumab) in metastatic colorectal cancer patients.More news on: Vascular Biogenics Ltd., Bristol-Myers Squibb Company, Healthcare stocks news, Read more ...